Cormorant Asset Management, LP Uni Qure N.V. Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $727,000 - $1.08 Million	-50,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $3.84 Million - $6.83 Million	-189,548 Reduced 79.13%	50,000 $1.04 Million
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $313,246 - $388,500	-10,452 Reduced 4.18%	239,548 $7.38 Million
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $2.65 Million - $3.8 Million	-75,000 Reduced 23.08%	250,000 $9.03 Million
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $4.29 Million - $5.68 Million	-119,157 Reduced 26.83%	325,000 $12 Million

Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $8.75 Million - $13.2 Million	194,157 Added 77.66%	444,157 $20 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $6 Million - $11.1 Million	-150,000 Reduced 37.5%	250,000 $11.9 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $18.6 Million - $37.3 Million	-500,000 Reduced 55.56%	400,000 $28.7 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $11.8 Million - $23 Million	300,000 Added 50.0%	900,000 $35.4 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $31.7 Million - $49.3 Million	600,000 New	600,000 $46.9 Million

148

34.1M

1.07M

603K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $209M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.